Key result
CYP2C9 and VKORC1 variants explained up to 30% of warfarin dose variability in European-Americans and 10% in African-Americans, and increased over-anticoagulation risk in European-Americans.
Why the study?
Do CYP2C9 and VKORC1 polymorphisms influence warfarin dose and anticoagulation outcomes differently among European-Americans and African-Americans?
Observational (n=575)
Do CYP2C9 and VKORC1 polymorphisms influence warfarin dose and anticoagulation outcomes differently among European-Americans and African-Americans?
CYP2C9 and VKORC1 polymorphisms explain a significant portion of warfarin dose variability, particularly in European-Americans, but their ability to predict over-anticoagulation risk is inconsistent across racial groups.
Answers are grounded in this paper and cite their sources.
Ancestry-specific genetic effects on warfarin dosing should not yet alter practice; leaves open prospective validation of risk prediction across groups.
AIMS: The influence of CYP2C9 and VKORC1 on warfarin dose, time to target International Normalized Ratio (INR), time to stabilization, and risk of over-anticoagulation (INR: > 4) was assessed after adjustment for clinical factors, intraindividual variation in environmental factors and unobserved heterogeneity. MATERIALS & METHODS: Common CYP2C9 and VKORC1 polymorphisms were assessed in 302 European-Americans and 273 African-Americans receiving warfarin. Race-stratified multivariable analyses evaluated the influence of CYP2C9 and VKORC1 on warfarin response. RESULTS & CONCLUSION: CYP2C9 and VKORC1 accounted for up to 30% of the variability in warfarin dose among European-Americans and 10% among African-Americans. Neither CYP2C9 nor VKORC1 influenced the time to target INR or stabilization among patients of either race, and neither influenced the risk of over-anticoagulation among African-Americans. The risk of over-anticoagulation was higher among European-Americans with variant VKORC1 1173C/T (p < 0.01) and marginally significant among those with variant CYP2C9 (p = 0.08) genotype. Although CYP2C9 and VKORC1 genotyping can facilitate individualized initiation of warfarin dose in African and European-Americans, the ability to predict the risk of over-anticoagulation is inconsistent across race. Identification of other factors that can predict such risk consistently in a racially diverse group will facilitate individualized maintenance of warfarin therapy.
No takes yet. Share an insight, caveat, or question.
Limdi et al. (2008) conducted an observational in Patients receiving warfarin (n=575). CYP2C9 and VKORC1 polymorphisms vs. Wild-type genotypes was evaluated on Warfarin dose, time to target INR, time to stabilization, and risk of over-anticoagulation (INR > 4) (p=<0.01). CYP2C9 and VKORC1 variants explained up to 30% of warfarin dose variability in European-Americans and 10% in African-Americans, and increased over-anticoagulation risk in European-Americans.
Synapse has enriched 10 related papers. Consider them for comparative context: